RAPT Therapeutics
We have no price for RAPT Therapeutics since 6 March 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
RAPT Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| RAPT Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads RAPT Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $58.00
- Range
- $58.00 – $58.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 5, 2026 | -9.12 | -0.82 | −1,008.2% |
| Nov 6, 2025 | -0.65 | -0.88 | +26.1% |
| Aug 7, 2025 | -0.65 | -0.61 | −6.6% |
| May 8, 2025 | -0.64 | -2.48 | +74.2% |
| Mar 6, 2025 | -1.14 | -0.45 | −153.3% |
| Nov 12, 2024 | -0.47 | -0.56 | +16.1% |
| Aug 8, 2024 | -0.71 | -0.74 | +4.1% |
| May 9, 2024 | -0.79 | -0.78 | −1.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about RAPT Therapeutics
Is RAPT Therapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the RAPT Therapeutics AI analysis
What does RAPT Therapeutics do?
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. It is in Biotechnology.
Who are RAPT Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with RAPT Therapeutics's.
Prices: daily closes to Mar 6, 2026. Fundamentals: company reports via invest-like data.